Home/Filings/4/0000950170-25-035489
4//SEC Filing

Daniell Richard 4

Accession 0000950170-25-035489

CIK 0000818686other

Filed

Mar 6, 7:00 PM ET

Accepted

Mar 7, 4:05 PM ET

Size

13.5 KB

Accession

0000950170-25-035489

Insider Transaction Report

Form 4
Period: 2025-03-05
Daniell Richard
Exec. VP, European Commercial
Transactions
  • Exercise/Conversion

    Restricted Share Units

    2025-03-0522,5760 total
    Ordinary Shares (22,576 underlying)
  • Exercise/Conversion

    Ordinary Shares

    2025-03-05+22,576119,345 total
  • Sale

    Ordinary Shares

    2025-03-05$15.91/sh22,576$359,27296,769 total
  • Sale

    Ordinary Shares

    2025-03-05$15.90/sh48,385$769,37048,384 total
  • Award

    Restricted Share Units

    2025-03-05+69,18269,182 total
    Ordinary Shares (69,182 underlying)
Footnotes (7)
  • [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
  • [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
  • [F3]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2024.
  • [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.795 to $16.01, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
  • [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.9 to $15.905, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
  • [F6]Restricted share units were granted on March 5, 2021, with 22,576 vested on each of March 5, 2022, March 5, 2023, March 5, 2024 and March 5, 2025.
  • [F7]Restricted share units were granted on March 5, 2025, with 17,295 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 17,297 vesting on March 5, 2029.

Documents

1 file

Issuer

TEVA PHARMACEUTICAL INDUSTRIES LTD

CIK 0000818686

Entity typeother

Related Parties

1
  • filerCIK 0001726096

Filing Metadata

Form type
4
Filed
Mar 6, 7:00 PM ET
Accepted
Mar 7, 4:05 PM ET
Size
13.5 KB